Eltrombopag
- Generic Name
- Eltrombopag
- Brand Names
- Promacta, Revolade
- Drug Type
- Small Molecule
- Chemical Formula
- C25H22N4O4
- CAS Number
- 496775-61-2
- Unique Ingredient Identifier
- S56D65XJ9G
- Background
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also bee...
- Indication
Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.
- Associated Conditions
- Chronic immune thrombocytopenia, Severe Aplastic Anemia (SAA), Thrombocytopenia
- Associated Therapies
- First-line Therapy
Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2020-05-06
- Target Recruit Count
- 30
- Registration Number
- NCT04371939
- Locations
- 🇷🇺
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP
- Conditions
- Interventions
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT04346654
- Locations
- 🇩🇪
Novartis Investigative Site, Kronach, Germany
Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia
- Conditions
- Interventions
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT04328727
- Locations
- 🇨🇳
Novartis Investigative Site, Kaohsiung, Taiwan
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
- Conditions
- Interventions
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2024-12-16
- Target Recruit Count
- 80
- Registration Number
- NCT04304820
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-12-03
- Target Recruit Count
- 15
- Registration Number
- NCT04269889
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04214951
- Locations
- 🇨🇳
Peking University Institute of Hematology, Beijing, Beijing, China
Eltrombopag in Chronic ITP
- Conditions
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 20
- Registration Number
- NCT04102033
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 25
- Registration Number
- NCT03948529
- Locations
- 🇫🇷
Hôpital Claude Huriez, CHU, Lille, France
Eltrombopag Vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
- Conditions
- Interventions
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 122
- Registration Number
- NCT03939637
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸Children's of Alabama, Birmingham, Alabama, United States
🇺🇸Phoenix CHildren's Hospital, Phoenix, Arizona, United States
The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT
- Conditions
- Interventions
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT03902041
- Locations
- 🇨🇳
Heamtology Department, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.